Indivior PLC

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BN4HT335
GBP
12.38
0.19 (1.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

8.26 M

Shareholding (Dec 2023)

FII

21.56%

Held by 53 FIIs

DII

70.29%

Held by 15 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 2,097 Million ()

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

19.79

stock-summary
Return on Equity

-80.17%

stock-summary
Price to Book

-11.18

Revenue and Profits:
Net Sales:
226 Million
(Quarterly Results - Jun 2025)
Net Profit:
13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
60.36%
0%
60.36%
6 Months
29.91%
0%
29.91%
1 Year
49.52%
0%
49.52%
2 Years
-34.04%
0%
-34.04%
3 Years
-20.18%
0%
-20.18%
4 Years
65.07%
0%
65.07%
5 Years
107.02%
0%
107.02%

Indivior PLC for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.38%
EBIT Growth (5y)
50.10%
EBIT to Interest (avg)
3.31
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
2.35
Tax Ratio
14.68%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.70%
ROCE (avg)
0
ROE (avg)
569.74%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
-11.18
EV to EBIT
8.04
EV to EBITDA
7.84
EV to Capital Employed
-6.28
EV to Sales
2.18
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 7 Schemes (8.15%)

Foreign Institutions

Held by 53 Foreign Institutions (21.56%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -4.60% vs 7.48% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 117.56% vs -346.47% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "226.10",
          "val2": "237.00",
          "chgp": "-4.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "55.40",
          "val2": "36.50",
          "chgp": "51.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.20",
          "val2": "7.10",
          "chgp": "57.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-126.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "13.50",
          "val2": "-76.90",
          "chgp": "117.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "235.10%",
          "val2": "140.50%",
          "chgp": "9.46%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.73% vs 20.21% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 103.72% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "929.70",
          "val2": "879.30",
          "chgp": "5.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "244.90",
          "val2": "230.10",
          "chgp": "6.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "32.10",
          "val2": "30.60",
          "chgp": "4.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-194.10",
          "val2": "-212.40",
          "chgp": "8.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.60",
          "val2": "1.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "239.10%",
          "val2": "236.00%",
          "chgp": "0.31%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
226.10
237.00
-4.60%
Operating Profit (PBDIT) excl Other Income
55.40
36.50
51.78%
Interest
11.20
7.10
57.75%
Exceptional Items
0.00
-126.80
100.00%
Consolidate Net Profit
13.50
-76.90
117.56%
Operating Profit Margin (Excl OI)
235.10%
140.50%
9.46%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -4.60% vs 7.48% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 117.56% vs -346.47% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
929.70
879.30
5.73%
Operating Profit (PBDIT) excl Other Income
244.90
230.10
6.43%
Interest
32.10
30.60
4.90%
Exceptional Items
-194.10
-212.40
8.62%
Consolidate Net Profit
1.60
1.60
Operating Profit Margin (Excl OI)
239.10%
236.00%
0.31%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 5.73% vs 20.21% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.00% vs 103.72% in Dec 2023

stock-summaryCompany CV
About Indivior PLC stock-summary
stock-summary
Indivior PLC
Pharmaceuticals & Biotechnology
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.
Company Coordinates stock-summary
Company Details
103-105 Bath Road , SLOUGH None : SL1 3UH
stock-summary
Tel: 44 1753 217800
stock-summary
Registrar Details